Meyer Handelman Co. bought a new stake in Corteva (NASDAQ:CTVA) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 317,849 shares of the company’s stock, valued at approximately $9,399,000.

Other hedge funds also recently bought and sold shares of the company. Landsberg Bennett & Dubbaneh LLC purchased a new stake in Corteva in the second quarter worth $565,000. State of Alaska Department of Revenue purchased a new stake in Corteva in the second quarter worth $3,556,000. Whittier Trust Co. of Nevada Inc. purchased a new stake in Corteva in the second quarter worth $796,000. Whittier Trust Co. purchased a new position in shares of Corteva in the second quarter valued at $1,723,000. Finally, Manchester Financial Inc. purchased a new position in shares of Corteva in the second quarter valued at $30,000.

In other Corteva news, Director Gregory R. Page bought 2,000 shares of Corteva stock in a transaction that occurred on Monday, June 3rd. The stock was acquired at an average cost of $25.49 per share, for a total transaction of $50,980.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Corteva stock traded up $0.46 during midday trading on Friday, hitting $28.48. 3,052,703 shares of the company’s stock were exchanged, compared to its average volume of 7,029,209. Corteva has a 52-week low of $24.35 and a 52-week high of $32.00. The stock’s 50-day moving average price is $27.43.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 13th. Investors of record on Wednesday, July 31st will be given a dividend of $0.13 per share. This represents a $0.52 annualized dividend and a yield of 1.83%. The ex-dividend date is Tuesday, July 30th.

CTVA has been the subject of several recent research reports. Monness Crespi & Hardt initiated coverage on Corteva in a research report on Wednesday, July 17th. They issued a “sell” rating and a $24.00 price target for the company. Nomura initiated coverage on Corteva in a research report on Monday, June 10th. They issued a “neutral” rating and a $28.00 price target for the company. Citigroup upgraded Atara Biotherapeutics from a “sell” rating to a “neutral” rating and lifted their price target for the company from $23.00 to $24.00 in a research report on Monday, June 3rd. SunTrust Banks initiated coverage on Corteva in a research report on Monday, June 3rd. They issued a “hold” rating and a $29.00 price target for the company. Finally, Morgan Stanley cut Meili from an “equal weight” rating to an “underweight” rating and reduced their price target for the company from $14.00 to $4.20 in a research report on Monday, June 3rd. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and six have given a buy rating to the company’s stock. Corteva presently has an average rating of “Hold” and an average price target of $30.79.

See Also: Buy Rating

Institutional Ownership by Quarter for Corteva (NASDAQ:CTVA)

Receive News & Ratings for Corteva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corteva and related companies with MarketBeat.com's FREE daily email newsletter.